Why AI Multiomics Will Replace Ultrasound in Liver Cancer Screening with Bharat Tewarie

In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.

Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio Genomics is trying to change that with HelioLiver, its blood-based test designed to improve early detection.

We discuss the limitations of ultrasound in liver cancer screening, the promise of AI-powered multiomics, and why early detection only matters if patients can actually access it. Bharat also shares how his clinical and commercial background shapes Helio’s strategy, from workflow design and physician adoption to partnerships, awareness, and the infrastructure needed to move from scientific validation to real clinical impact.

This is a practical conversation about liver cancer, access, commercialization, and what it takes to turn better diagnostics into better outcomes.

Key takeaways:

🔹 Why liver cancer surveillance still leaves too many high-risk patients undetected

🔹 How AI-powered multiomics and HelioLiver could improve early liver cancer detection

🔹 Why access and workflow matter just as much as scientific performance

🔹 How partnerships can accelerate commercialization and patient reach

🔹 What Helio Genomics is building beyond HelioLiver as it expands its platform

Guest: Bharat Tewarie, MD, MBA

CEO at Helio Genomics

LinkedIn: https://www.linkedin.com/in/bharattewarie/

Host: David Filby

Founder and CEO of Elevra Consulting

LinkedIn: https://www.linkedin.com/in/davidfilby/

Chapters:
00:00 Introduction to Bharat Tewarie and Helio Genomics
01:42 Bharat’s journey from medicine to business
06:25 The evolution of diagnostics, omics, and AI
10:36 Helio Genomics’ mission and differentiators
12:03 Unmet needs in liver cancer surveillance
14:01 Awareness, access, and clinical workflow challenges
19:10 The role of partnerships in commercialization
26:27 Growth strategy and the future of diagnostics

🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.